Results 61 to 70 of about 28,236 (118)

Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes. [PDF]

Diabetes Obes Metab
Sørensen KK, Yazdanfard PDW, Zareini B, Wood-Kurland HK, Pedersen-Bjergaard U, Andersen MP, Michelsen J, Imberg H, Lind M, Hallström S, Lanzinger S, Munch A, Ohlendorff JS, Gerds TA, Torp-Pedersen C, REDDIE Consortium.   +15 more
europepmc   +1 more source

Association of Dipeptidyl Peptidase-4 Inhibitors with Glaucoma Risk in Patients with Type 2 Diabetes: A Nationwide Cohort Study. [PDF]

Ophthalmol Sci
Lu YA, Tien PT, Cheng YD, Hsieh YW, Cho DY, Tsai SF, Weng CH, Lin HJ, Lin HJ, Wang IJ, Chou CC.   +10 more
europepmc   +1 more source

Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study. [PDF]

Diabetes Obes Metab
Tang WC, Reynier P, Douros A, Yu OHY, Platt RW, Filion KB.   +5 more
europepmc   +1 more source

Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease. [PDF]

Gut Liver
Ko Y, Hur MH, Park Y, Park J, Shin H, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ.   +10 more
europepmc   +1 more source

Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors.

JAMA Netw Open
Turchin A, Petito LC, Hegermiller E, Carnahan R, DeVries A, Goel S, Lansang MC, McDonnell ME, Nair V, Priest E, Willey VJ, Kaul AF, Hernán MA.   +12 more
europepmc   +1 more source

Heterogeneous effects of sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors on nephrolithiasis in older adults with type 2 diabetes. [PDF]

Pharmacotherapy
Radwan RM, Huang W, Li Y, Shao H, Guo Y, Zhang Y, Fonseca V, Shi L, Huang Y, Schatz D, Bian J, Guo J.   +11 more
europepmc   +1 more source

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas. [PDF]

Clin Transl Sci
Chen WS, Lin TM, Chang YS, Shen YC, Hsu HC, Kuo TT, Chen SC, Chen JH, Chang CC.   +8 more
europepmc   +1 more source

Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology

Journal of Diabetes Investigation, 2019
Takaaki Murakami, Daisuke Yabe, Nobuya Inagaki   +2 more
doaj   +1 more source

Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy? [PDF]

World J Diabetes
Mohammadi S, Al-Harrasi A.
europepmc   +1 more source

Evaluation of a Community Pharmacist-Led Intervention Program for Early Detection of Gastrointestinal Adverse Events of Dipeptidyl Peptidase-4 Inhibitors: A Multicenter, Non-Randomized Comparative Study. [PDF]

Pharmacy (Basel)
Funabashi A, Ito H, Maeda M, Hasegawa Y, Tsukioka R, Onda M.   +5 more
europepmc   +1 more source